GLP-1 Receptor Agonist Repurposing Across Indications: Mechanism, Evidence and Trial Sequencing
DOI:
https://doi.org/10.5281/zenodo.22649327Keywords:
GLP-1 Receptor Agonist Repurposing Across Indications;, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
GLP-1 Receptor Agonist Repurposing Across Indications is an area of active development in translational medicine, with evidence
that has accumulated unevenly across its component questions. We review the current evidence base for glp-1 receptor agonist
repurposing across indications, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on
where practice has converged and where it continues to vary, and set out the practical considerations relevant to a service
considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently available,
rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1093/medlaw/fwad013
Brankovic K, Kowalczyk B, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.2196/89834
Castellani R, Ristic C, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1007/s10916-024-02104-9
Dumitrescu A, Andric D, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1896184
Eriksdottir B, Brankovic E, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3390/diagnostics15162117
Farkas I, Ionescu F, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.4103/jrpp.jrpp_20_65
Grabowski P, Petrescu G, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.3389/fdgth.2026.1763884
Hendriksen W, Wojcik H, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/48297
Ionescu F, Foscarini I, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1007/s00330-025-12031-z
Jankowiak G, Grabowski J, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3389/fdgth.2026.1699005
Kowalczyk N, Novotna K, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.3389/fdgth.2026.1834800
Lindqvist U, Urbanek L, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.2196/69678
Marchetti D, Doncheva M, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.7759/cureus.46454
Novotna E, Eriksdottir N, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1016/j.ssci.2025.107028
Ostrowski L, Lindqvist O, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.2196/48633
Petrescu S, Szabo P, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1371/journal.pone.0305949
Quintero B, Balogh Q, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.1371/journal.pdig.0000514
Ristic C, Castellani R, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.17219/acem/208596
Szabo J, Jankowiak S, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.7759/cureus.104086
Tarasov Q, Quintero T, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1038/s41746-023-00852-5
Urbanek Z, Zielinski U, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1016/j.mayocpiqo.2022.09.004
Vasquez A, Alvez V, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1177/08404704241291226
Wojcik H, Hendriksen W, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1093/medlaw/fwad013
Zielinski O, Ostrowski Z, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.2196/89834
Andric V, Vasquez A, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1007/s10916-024-02104-9
Balogh E, Emmerich B, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1896184
Chiriac F, Farkas C, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3390/diagnostics15162117
Doncheva M, Marchetti D, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a validation study". Trials 22(2017): 377-383. DOI: 10.4103/jrpp.jrpp_20_65
Emmerich T, Tarasov E, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.3389/fdgth.2026.1763884
Foscarini C, Chiriac F, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/48297
Alvez D, Dumitrescu A, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1007/s00330-025-12031-z
Brankovic K, Kowalczyk B, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3389/fdgth.2026.1699005
Castellani R, Ristic C, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.3389/fdgth.2026.1834800
Dumitrescu A, Andric D, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.2196/69678
Eriksdottir B, Brankovic E, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.7759/cureus.46454
Farkas I, Ionescu F, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1016/j.ssci.2025.107028
Grabowski P, Petrescu G, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.2196/48633
Hendriksen W, Wojcik H, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1371/journal.pone.0305949
Ionescu F, Foscarini I, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a scoping review". JAMA 44(2020): 498-506. DOI: 10.1371/journal.pdig.0000514
Jankowiak G, Grabowski J, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.17219/acem/208596
Kowalczyk N, Novotna K, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.7759/cureus.104086
Lindqvist U, Urbanek L, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1038/s41746-023-00852-5
Marchetti D, Doncheva M, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1016/j.mayocpiqo.2022.09.004
Novotna E, Eriksdottir N, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1177/08404704241291226
Ostrowski L, Lindqvist O, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1093/medlaw/fwad013
Petrescu S, Szabo P, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.2196/89834
Quintero B, Balogh Q, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1007/s10916-024-02104-9
Ristic C, Castellani R, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1896184
Szabo J, Jankowiak S, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3390/diagnostics15162117
Tarasov Q, Quintero T, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.4103/jrpp.jrpp_20_65
Urbanek Z, Zielinski U, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.3389/fdgth.2026.1763884
Vasquez A, Alvez V, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/48297
Wojcik H, Hendriksen W, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1007/s00330-025-12031-z
Zielinski O, Ostrowski Z, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3389/fdgth.2026.1699005
Andric V, Vasquez A, et al. "GLP-1 Receptor Agonist Repurposing Across Indications: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.3389/fdgth.2026.1834800
